Use of tranexamic acid in dogs with primary immune thrombocytopenia
The aim of this feasibility study is to evaluate the use of tranexamic acid and its safety when used alongside standard therapy in dogs with primary immune thrombocytopenia (ITP).
This was a cohort feasibility study involving 10 dogs diagnosed with primary ITP that received standard therapy for ITP including corticosteroids, a single dose of vincristine, and omeprazole. Dogs were randomly divided into either the control group (n = 6) or the group receiving tranexamic acid (TXA group, n = 4).
The mean time from the start of treatment until remission was five days in the TXA group and six days in the control group (P = 0.69). Two dogs, one in each group, did not achieve remission.
Clinical bleeding scores were not significantly different between both groups (p = 0.43). The median blood volume administered was 37.5 ml/kg for the TXA group and 9.72 ml/kg for the control group (p = 0.084). Three out of the four dogs receiving TXA of 20 mg/kg IV started vomiting within 15 min of administration and were given a reduced dose of 15 or 10 mg/kg IV.
In conclusion, tranexamic acid did not confer a clinical benefit in this small cohort study and was associated with a high incidence of vomiting.
Gerard Olivares, et al. “Use of tranexamic acid in dogs with primary immune thrombocytopenia: A feasibility study.” Front Vet Sci. 2023 Mar 22; 10:946127. doi: 10.3389/fvets.2023.946127.
Comments
Related Articles
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment